Beta Bionics Appoints Gilad Glick to the Board of Directors and Veena Rao, Ph.D. as Chief Commercial Officer
May 10, 2022 05:00 ET
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Gilad Glick, former Chief Executive Officer,...
The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes
April 30, 2022 04:00 ET
|
Beta Bionics, Inc.
The trial achieved key primary and secondary endpoints, demonstrating improved outcomes over standard of care for people living with type 1 diabetes.The study population — 440 adults and children 6...
Pivotal Trial Results of the iLet® Bionic Pancreas To Be Presented at ATTD
April 25, 2022 05:00 ET
|
Beta Bionics, Inc.
Dr. Steven J. Russell will present the results from the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial at the International Conference on Advanced Technologies & Treatments for...
Throne Biotechnologies Wins '5 Best BioTech Companies To Watch' Award From The Silicon Review
March 28, 2022 09:00 ET
|
Throne Biotechnologies Inc
PARAMUS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies (Throne), one of the global-leading biotech companies aiming to find a cure for type 1 diabetes and other autoimmune...
Beta Bionics Announces Executive Leadership and Board Transitions in Preparation for Commercialization of the iLet® Bionic Pancreas System
March 02, 2022 16:15 ET
|
Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Ed Damiano, President & CEO of Beta...
Throne Biotechnologies Launches Equity Crowdfunding to Support Phase 2 Clinical Trials in Type 1 Diabetes and Alopecia Areata
February 28, 2022 09:00 ET
|
Throne Biotechnologies Inc
PARAMUS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies, one of the global-leading biotech companies aiming to find a cure for type 1 diabetes, announced the launch of their...
vTv Therapeutics Shares Updated Corporate Presentation
January 13, 2022 08:30 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with...
vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
December 06, 2021 17:19 ET
|
vTv Therapeutics Inc.
-Workforce reduction of 65% -Prioritization of lead program TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients HIGH POINT, N.C.,...
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
November 09, 2021 08:30 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the...
SymbioCellTech Demonstrates Preclinical Efficacy of Proprietary and Novel Human Neo-Islets™ Technology in STZ-Diabetic NOD-SCID Mice
October 28, 2021 14:30 ET
|
SymbioCellTech, LLC
SALT LAKE CITY, Oct. 28, 2021 (GLOBE NEWSWIRE) -- SymbioCellTech (SCT) announced today the publication of a paper demonstrating the potency and efficacy of its innovative and proprietary human...